Onk Therapeutics
ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting solid and hematological cancers.
Onk Therapeutics has raised €26M across 2 funding rounds, most recently a Series A round in Jan 2022. Based in Galway, Ireland; founded 2015; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€26M
€25,843,647
Funding rounds
2
Investors
0
distinct backers
Active since
2020-10
latest 2022-01
Funding by year
EUR raised per yearOnk Therapeutics — funding by year — interactive chart.
Data table
| Onk Therapeutics — funding by year | |
|---|---|
| 2020 | €6.8M |
| 2022 | €19M |
Signals
Medium confidenceRaise-next likelihood10
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ 11y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-01-07 | Series A | €19M | — | View deal → |
| 2020-10-19 | Other | €6.8M | — | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Wayflyer€2.1BIreland · E-commerce
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
Global coverage: FundingData